ArticleAnnals of translational medicine2020
Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis.International immunopharmacology · 2021Pooled it
- Pericarditis in a Child with COVID-19 Complicated byViruses · 2025Article
- Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study.Journal of medical virology · 2024Article
- Methodology and experiences of rapid advice guideline development for children with COVID-19: responding to the COVID-19 outbreak quickly and efficiently.BMC medical research methodology · 2022Article
- Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study.Frontiers in immunology · 2022Article
- Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study.BMC pulmonary medicine · 2021Article
- Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.Journal of clinical immunology · 2021Article
- Coronavirus Disease 2019 Infection among Children: Pathogenesis, Treatment, and Outcome.Journal of pediatric intensive care · 2021Review
- Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.Microorganisms · 2021Review
- Development and application of therapeutic antibodies against COVID-19.International journal of biological sciences · 2021Review
- Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies.Translational pediatrics · 2021Article
- Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study.Frontiers in immunology · 2021Article
- Severe immune thrombocytopenia in a critically ill COVID-19 patient.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Deciphering SARS-CoV-2 Virologic and Immunologic Features.International journal of molecular sciences · 2020Review
- COVID-19: The Immune Responses and Clinical Therapy Candidates.International journal of molecular sciences · 2020Review
- Rapid advice guidelines for management of children with COVID-19.Annals of translational medicine · 2020Review
- Pathophysiology of Cardiovascular Complications in COVID-19.Frontiers in physiology · 2020Review
- Therapeutic interventions for COVID-19: a living overview of reviews.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous immunoglobulin (IVIG) is usually used as supportive therapy, but the treatment of COVID-19 by IVIG is controversial. This rapid review aims to explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19.
methodsWe systematically searched the literature on the use of IVIG in patients with COVID-19, severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS), including both adults and children. We assessed the risk of bias and quality of evidence and reported the main findings descriptively.
resultsA total of 1,519 articles were identified by initial literature search, and finally six studies met our inclusion criteria, included one randomized controlled trial (RCT), four case series and one case report involving 198 patients. One case series showed the survival of COVID-19 patients with acute respiratory distress syndrome (ARDS) was not improved by IVIG. One case report showed high-dose IVIG could improve the outcome of COVID-19 adults. Three observational studies showed inconsistent results of the effect of IVIG on SARS patients. One RCT showed that IVIG did not reduce mortality or the incidence of nosocomial infection in adults with severe SARS. The quality of evidence was between low and very low.
conclusionsThe existing evidence is insufficient to support the efficacy or safety of IVIG in the treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.